An introduction of recombinant DNA technology to pharmaceutical industry did NOT allow for:
a. Improved drug safety
b. High level of drug modification/alteration
c. Mass-production of the biopharmaceuticals
d. Higher average prices of the major biopharmaceuticals
e. All of the above were the consequences of the switch to recombinant DNA technology in pharmaceutical industry